Clinical trial registry record

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated November 8, 2023.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02581891
Last registry update
November 8, 2023
Status
Completed
Phase
Phase 4
Sponsor
Bayer
Enrollment
287
Countries
Australia, Canada, France, Germany, Hungary, Italy, Spain, United Kingdom
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
287
Population
ALL · 50 Years
Duration
2015-11-19 to 2019-04-26
Intervention
Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
Comparator
Late-start T&E / Arm 2
Outcomes measured
Change in BCVA as Measured by the ETDRS Letter Score — From Week 16 to Week 104; Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 104 Compared With Baseline — at Week 104; Change in BCVA From Baseline to Week 52, Baseline to Week 104, and Week 16 to Week 52 — from baseline to Week 52, basel…; Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 52 Compared With Baseline — At week 52; Percentage of Participants Gained 3-line at Week 52 and Week 104 Compared With Baseline — At Week 52 and Week 104; Change in Central Retinal Thickness (CRT) — From baseline to Week 52, baseline to Week 104, Week 16 to Week 52, and Wee…; Number of Study Drug Injections From Baseline to Week 52 and Baseline to Week 104 — At Week 52 and Week 104; Duration of Last Treatment Interval — Early-Start T&E: from week 16 up to Week 104 or early termination; Late-Start T&E…; Percentage of Participants Requiring Retreatment at 8 Weeks, 10 Weeks, 12 Weeks, 14 Weeks, and 16 Weeks as the Last Tre…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 80%Title contains controlled term: age-related macular degeneration. Title supplies longevity context: aging, age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON